Key Stats for Roivant Sciences Stock
- Price change for Roivant Sciences stock in the last 1 year: 180%
- $ROIV Stock Price as of Aug. 28: $35
- 52-Week High: $38
- $ROIV Stock Price Target: $42
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Roivant Sciences (ROIV) stock fell 8% on Friday, even after the FDA approved LISRAYA, the first oral treatment for adults with dermatomyositis. The drop wiped out roughly $720 million in implied equity value, reminding investors that good news doesn’t always move a stock as expected.
The approval itself was strong. LISRAYA, a once-daily 30-milligram tablet, cleared the FDA based on a 52-week Phase 3 study of 241 patients.
Patients on the approved dose saw their Total Improvement Score reach 46.5, compared to 31.2 for those on placebo, a meaningful 15.3-point gap.
Benefits showed up as early as week four and held through the full year, with treated patients also cutting back steroid use more than those on placebo.
JPMorgan analyst Brian Cheng estimates peak U.S. sales could top $2 billion by the early 2030s, roughly 7.6% of Roivant Sciences stock’s current market value.
That said, dermatomyositis is a rare disease, affecting fewer than 5,000 people in the U.S., which limits how large this single drug’s revenue can ultimately grow.
Pricing hasn’t been disclosed yet, and Roivant says eligible patients could pay as little as zero dollars a month, though actual revenue will hinge on how insurers handle coverage.
See analysts’ growth forecasts and price targets for Roivant Sciences stock (It’s free) >>>
What the Market Is Telling Us About Roivant Sciences Stock
The pullback in Roivant Sciences stock suggests investors had already priced in much of the approval news, and attention is now shifting to execution.
Getting FDA clearance is one thing, but turning that into real prescriptions, payer coverage, and a defined price point is the next test. Until those pieces come into focus, some investors appear content to take profits rather than chase the stock higher.
The company isn’t starting this launch short on resources. Roivant ended the June quarter with $3.9 billion in cash, restricted cash, and marketable securities, giving it plenty of runway to fund both the LISRAYA rollout and its broader pipeline.
That said, the quarter also showed a net loss of $290.6 million and just $1.4 million in revenue, underscoring that Roivant Sciences stock remains a story about future potential rather than current profitability.
There are also real risks tied to the drug itself.
LISRAYA carries boxed warnings for serious infections, malignancy, major cardiovascular events, and thrombosis, and any slowdown in specialty-drug reimbursement could slow adoption.
For now, the approval clears the biggest clinical hurdle, but the market seems to be waiting for clearer signals on pricing and payer coverage before rewarding Roivant Sciences stock further.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does Roivant Sciences Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
